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INTRODUCTION
The development of newborn screening is one of the most significant advancements in
public health genetics. It is the practice of testing all babies for certain disorders, diseases and
conditions that may hinder their normal development. In the United States alone, more than four
million newborns are screened shortly after birth for certain genetic diseases, in addition for
screening for non-genetic conditions. 1 While early detection and treatment can help prevent
physical and intellectual disabilities, as well as life threatening illnesses, the early detection of
some disorders that are required to be tested, cannot be cured, but rather, through therapies and
intervention may be treatable or preventable.
This concept of ‘treatability’ is interesting considering that several diseases not required
to be screened as recommended by the Department of Health and Senior Services (DHS) and
state law, through intervention and therapies, are treatable. This perhaps should reveal the most
obvious aspect of newborn screening in the United States- that the diseases, disorders and
conditions screened vary from state to state.
The Supreme Court’s recent decision to uphold the Patient Protection and Affordable
Care Act (ACA) supports the importance of recommending the nation-wide insurance coverage
of diseases and disorders that are required to be tested through newborn screening. It also brings
us closer to the institution of these federally recommended diseases in state newborn screening
panels. Importantly, the law also stipulates that insurance companies must pay for the newborn
screening of diseases recommended by DHS. This is a great achievement in the effort to assure

1

See NIH Program Explores the Use of Genomic Sequencing in Newborn Healthcare,
http://www.nih.gov/news/health/sep2013/nhgri-04.htm, (last visited Dec. 8, 2013).
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that all newborn babies are tested for these diseases and disorders that may save or improve the
quality of their young lives.2.
Despite this laudable achievement in the law, it is important to note that not all of the
disorders, conditions and diseases generally required to be tested under the federal panel can be
cured. Rather, many of these conditions, can be treated or their onset delayed through the early
detection of the presence of the gene. This presents several ethical considerations and questions
as to why certain diseases in this non-treatable category are not tested through the newborn
screening process.
In recent years, in particular, there has been a public push to add neurological diseases to
newborn screening panels across the country. Such diseases include Alzheimer’s disease and
Krabbe disease, also referred to as globoid cell leukodystrophy. Alzheimer’s disease is an
irrevererable, progressive brain disease that slowly deteriorates memory and thinking abilities.3
At its most debilitating stages, individuals with Alzheimer’s disease must rely on others to
complete the simplest of tasks.4 Krabbe disease is an untreatable neurological disorder that leads
to extreme muscle weakness and slowed mental and physical development.5 It eventually leads
to death.6 New Jersey and New York are among the few states to test for Krabbe’s disease.
This paper will the will present a comparative analysis as to the diseases tested under
newborn screening under the ACA, New Jersey and New York state law. It will discuss the
significance of the ACA to newborn screening in the United States. This paper will also focus
on the inclusion of Krabbe’s disease to New York and New Jersey’s Newborn screening panels
2

See Health Care Reform Law Benefits Children with Genetic Diseases: Despite the law’s benefits, many questions
about coverage remain, http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.35676/full, (Last visited Dec. 8, 2013).
3
See National Institute off Aging, Alzheimer’s disease Fact; Sheet
http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-fact-sheet (Last visited Dec. 8, 2013).
4
See id.
5
See Krabbe Disease, http://ghr.nlm.nih.gov/condition/krabbe-disease, (Last visited Dec. 8, 2013).
6
See id.
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and why its inclusion represents a milestone so that other neurological disorders, such as Earlyonset Alzheimer’s disease can be included. It will conclude with why Early-Onset Alzheimer’s
should be added to the federally recommended Uniform Screening Panel.
Part I of this paper will focus on the process and history of newborn screening in the
United States. Part II of this paper will explore the changes made to newborn screening under
the ACA and what is required of insurance companies under the Act. It will also break down the
diseases approved by the Secretary of DHS to be included in the Recommended Newborn
Screening Panel (RNSP) and what diseases are curable, treatable through intervention, and not
treatable. Part III will explore the diseases required to be screened under New Jersey and New
York’s newborn screening laws. Part IV will explore what Early Alzheimer’s disease is and will
argue that it should be added to the list of diseases screened at the federal level. It will also
discuss therapies and interventions that can reduce the risk of the disease and urge that the
availability of these interventions supports its inclusion on the federal RNSP. This writing will
conclude with Part V which will close with why Early-Onset Alzheimer’s disease should be add
to newborn screening panels, both in New York and New Jersey in addition to the federally
recommended list of diseases screened for.

IV.

THE PROCESS AND HISTORY OF NEWBORN SCREENING

Newborn screening is a medical test that is performed on infants shortly after birth that
occurs by taking a sample of an infant’s blood and analyzing it for abnormal genes types,

4

enzymes, metabolites and other chemicals.7 This test was established to diagnosis and detect the
presence of life-threatening disorders in infants.8 The newborn screening procedure is a noninvasive blood test in which a small sample of blood is collected by simply taking a sample of
blood from an infant’s heal.9 It is then analyzed for abnormal gene types, enzymes, metabolic
and other chemicals that may lead to the diagnosis of a disorder.10 This is usually performed in a
laboratory and the results are provided to medical professionals usually within twenty-four (24)
hours.11
Dr. Robert Guthrie developed the newborn screening test in the 1960s. Dr. Guthrie
initially began his career as a principal cancer scientist that the Roswell Park Cancer Institute in
Buffalo, New York. 12

After the birth of his second son John, who was born with

phenylketonuria (PKU), he then altered his career and dedicated his research to altering and
measuring phenylalanine levels in the blood of infants who acquired PKU in order to find a cure
and treat his son.13 Through his research, he developed the newborn screening test, a relatively
easy procedure. Basically, within the first twenty-four hours of life, three to four droplets of an
infant’s blood are collected and placed on special filter paper.14 The sample is then dried and
sent out to a special laboratory for testing. The results are received usually within a day. The
most important result was that through the Guthrie method of newborn screening, a definitive
therapy for treating PKU was able to be administered to infants before the neurotoxicity that

7

See Association of Public Health Laboratories, What is newborn Screening,
http://www.aphl.org/aphlprograms/newborn-screening-and-genetics/50th-Anniversary-of-NewbornScreening/Pages/What-is-Newborn-Screening.aspx, (Last visited Dec. 8, 2013).
8
See id.
9
See id.
10
See id.
11
See id.
12
See Jason Gonzalez & Monte S. Willis, Robert Guthriem MD, PhD, Clinical Chemistry/Microbiology,
LABMEDICINE, 40, 748-749 (2009).
13
See id.
14
See id.
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resulted from PKU became fatal.15 Thus, it helped to save the lives of the infants affected by this
debilitating disease.
In the United States, newborn screening began with the testing for genetic disease PKU.
PKU is a genetic disorder the results in an individual’s inability to produce the specific enzyme
that causes a buildup of the amino acid phenylalanine.16 An accumulation of the amino acid
phenylalanine produces several physical and mental symptoms such as stunted growth, seizures,
hyperactivity, sudden uncontrolled movements of the arms and legs, skin rashes and mental
retardation.17 In addition, phenylalanine affects the body’s production of melanin, the pigment
that determines the hair and skin color of an individual.18 Therefore, infants with this condition
often have lighter skin, hair and eyes than their brothers and sisters. 19 Fortunately, if PKU is
diagnosed within the first few days of life, it is treatable and the majority of its symptoms can be
avoided or reversed. 20

This is accomplished by constricting the amount of phenylalanine

consumed in the infant’s daily diet.21 It also requires that a doctor or registered dietician closely
monitor the individuals diet.22 Infants, who are treated for PKU within the first few weeks of
life, are able to lead normal, healthy lives.23
The original purpose of newborn screening had two main goals. 24 First, the programs
were created to the monitor the health of the infant population in the United States.25 Second,

15

See id.
See id.
17
See id.
18
See A.D.A.M. Medical Encyclopedia, Phenylketonuria,
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002150/, (Last visited Dec. 6, 2013)
19
See id.
20 See id.
21 See id.
22 See id.
23 See id.
16

24

See Rachel L. Schweers, Ph.D, Newborn Screening Programs: How Do We Best Protect Privacy Rights While

Ensuring Optimal Newborn Health?, 61 DEPAUL L. REV. 869, 875 (2012).
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the programs were intended to detect metabolic abnormalities in infants that were known, at the
time, to have severe consequences such as death, that were easily discoverable through a simple
blood test.26
With this scientific advancement, and in response to advocacy of geneticists, the medical
community and parents, states began establishing newborn screening programs. The first state
to mandate a newborn screening programswas Massachusetts.27 They started testing for PKU
and added other diseases as they were discovered.28 By the early 1970’s all fifty states created
programs with the support of the medical community. 29 They followed the Massachusetts lead,
which resulted in approximately ninety percent of all newborns in the United States being tested
for PKU.30
For the next ten years, states continued to add disorders to their newborn screening
program. One important aspect of these new additions to newborn screening programs was that
only disorders were included if treatment could avert serious harm to the affected child.31 From
then on, newborn screening has become a permanent part of infant health care in the United
States.

Today, all states, including the District of Columbia have implemented successful

newborn screening programs to test for numerous metabolic and genetic disorders.32 Although,
it is important to note that not all of the diseases recommended by the RNSP are tested for in
each state.

25

See id.
See id.
27
See id. Diane B. Paul, The History of Newborn Phenylketonuria Screening in the U.S., in Final Report of the Task
Force on Genetic Testing, Appendix 5 (Neil A. Holtzman & Michael S. Watson eds., 1997).
28
See id.
29
See Ellen Wright Clayton, State Run Newborn Screening In The Genomic Era, Or How To Avoid Drowning When
Drinking From A Fire Hose, 38 J.L. MED. & ETHICS 697 (2010).
30
See id.
31
See id.
32
See id.
26
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A. The Expansion of Diseases Tested in Newborn Screening Programs

As a result of the ever-increasing advancements in science through technology and
genetics, states have continued to expand the disorders, diseases and conditions tested for in their
newborn screening programs.

Many of these diseases included not only diseases that benefit

from intervention at infancy, such as PKU, but also for diseases for which there is no known
treatment, cure or intervention available. Such diseases include Huntington’s disease and some
forms of Krabbe Disease.33 In addition, diseases for which a prediction of diagnosis is given
based upon an individual’s genetics are also included.34
The accuracy and validity of predicting a diagnosis of a certain disease or disorder is, to
date, one of the most controversial aspects of newborn screening programs. In fact, some
medical professional organizations do not fully support predictive testing to reveal the propensity
of diseases with no exiting treatment or for which the disease does not physically present itself
until post-childhood.35 However, despite this controversy, in recent years there has been a
significant drive from advocacy, interest groups, and lobbyists to add diseases such as Krabbe's
disease, also known as Globoid Cell Leukodystroph, to the list of conditions screened.36 This is
significant because the onset of Krabbe disease varies.37
In 1968, Maxwell Grove Wilson, the then Principal Medical Officer at the Ministry of
Health in London, England, and Gunner Jungner, the then Chief of the Clinical Chemistry
33

See About Newborn Screening, Conditions Screened by State, http://www.babysfirsttest.org/newbornscreening/states, (last visited Dec. 8, 2013).
34
See Beth A. Tarini et al., Not Without My Permission: Parents' Willingness to Permit Use of Newborn Screening
Samples for Research, 13 PUB. HEALTH GENOMICS 125,127 (2010).
35
See Beth A. Tarini et al., Parents' Interest in Predictive Genetic Testing for Their Children when a Disease Has
No Treatment, 124 PEDIATRICS 432, 435 (2010).
36
See Krabbe Newborn Screening, Information for Parents whose Baby Screened Positive for Krabbe Disease,
http://www.huntershope.org/site/PageServer?pagename=unbs_krabbe_newborn_screening, (Last visited Dec. 7,
2013).
37 Please refer to Part 3, section A of this paper for a more detailed explaination on the onset of Krabbe disease.
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Department of Sahlgren’s Hospital in Gothenburg, Sweden, published a report that established a
set of classic criteria, which still remain influential in defining what disorders and diseases
should be deemed suitable for inclusion in newborn screening and genetic screening both on the
state and federal level. 38 The report was entitled, Principles and Practice of Screening for
Disease.39
Despite being established many years ago, these core principles remain relevant today.40
The principles are generally as follows. First, the disease must be well defined and serious.41
Second, there must be an accurate testing method available.42 Third, the costs of the test must be
reasonable. Fourth, there must be available treatment for the disorder.43 And last, there must be
adequate medical management facilities to refer infants for confirmatory diagnosis and
treatment.44
With this framework in mind, the next part of this paper will explore the significance of
the ACA followed by an analysis of newborn screening laws in New Jersey and New York.

V.

NEWBORN SCREENING IN THE PATIENT PROTECTION AND AFFORDABLE CARE ACT

The single most significant development in healthcare law was the Supreme Court’s
decision to uphold the Patient Protection and Affordable Care Act (ACA).

38

In the landmark case

See Anne Andermann, Ingeborg Blancquaert, Sylvie Beauchamp & Véronique Déry, Revisiting Wilson And
Jungner In The Genomic Age: A Review Of Screening Criteria Over The Past 40 Years, BULLWORLD HEALTH ORG,
2008 Apr;86(4):317-9.
39
See id.
40
See id.
41
See Maxwell Grove Wilson & Gunner Jungner, Principles and Practice of Screening for Disease, 27-8,WORLD
HEALTH, PUBLIC HEALTH PAPERS NO. 34 (1968).
42
See id.
43
See id.
44
See Eileen M. McKenna, The Mandatory Testing of Newborns for HIV: Too Much, Too Little, Too Late, 13
N.Y.L. SCH. HUM. RTS. 307, 327-28 (1997).
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National Federal of Independent Business v. Sibelius, several states filed suit against Secretary
Sibelius based upon the constitutionality of the Patient Protection and Affordable Care Act
signed into law by President Barak Obama on March 23, 2010.
The Court found that the Medicaid expansion mandate under the Affordable Care Act was
unconstitutional, because states did not have adequate notice to voluntarily consent to the new
Medicaid expansion provision. In addition, the Court held that if a state did not comply with the
new law, the Secretary could withhold all of a state’s existing federal Medicaid funds.45 Despite
this, the majority of the Supreme Court still found that this issue was appropriately remedied
through the ACA. Thus, the ACA expansion was upheld.
As a result of this ruling by the Supreme Court, all provisions and mandates in the ACA
remain effective. This signifies an important landmark for newborn screening. According to the
ACA, insurance companies are now required to provide coverage for newborn screening of
diseases that are federally recommended46.
Section 2713, Coverage for Preventable Health Services of the ACA states:
(a) IN GENERAL- a group health place and a health insurance insurer offering group or
individual health insurance coverage shall, at a minimum provide coverage for and
shall not impose any cost sharing requirements for(3) With respect to infants, children, adolescents, evidence-informed
preventative care and screenings provided for in the comprehensive guidelines
supported by the Health Resources and Services Administration.47
This provides that all the conditions added to the panel of diseases recommended to be screened
by the Secretary’s Discretionary Advisory Committee on Heritable Diseases in Newborns and
Children must be covered by insurance, regardless of whether or not a state requires screening
for that specific newborn disease. This is significant because not all states test for the diseases

45

See id.
The Patient Protection and Affordable Care Act, 42 U.S.C. § 2713 (2010).
47
See id.
46
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recommended by the federal government. Therefore, mandating that insurance pay for all the
diseases recommended by the federal government provides newborns with more thorough
screening exams and can save more infant lives.
The Discretionary Advisory Committee on Heritable Disorders in Newborns and
Children was established under the Public Health Service Act (PHS), 42 U.S.C. 217, Advisory
Councils or Committees.48 The Committee on Heritable Diseases in Newborns and Children
recommends that every newborn screening panel in the country screen for the thirty-one core
disorders and twenty-six secondary disorders recommended by the Uniform Screening Panel.49
The Uniform Screening Panel defines primary disorders as those disorders for which medical
evidence suggests that there is a medical benefit for detecting the disorder in infants. 50 The
Panel defines secondary disorders as those disorders that can be detected while screening for the
primary disorders. 51 These disorders include metabolic disorders 52 , Endocrine Disorders 53 ,
Hemoglobin Disorders54 and other disorders such as Biotinidase deficiency, Critical Congenital
Heart Disease, Cystic Fibrosis, Classic Galactosemia, Hearing loss and severe combined

48

See Discretionary Advisory Committee on Heritable Disorders In Newborns and Children,
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/, (Last visited Dec. 6, 2013).
49
See id.
50
See Virginia A. Moyer, Ned Calonge, Steven M. Teutsch, and Jeffrey R. Botkin, on behalf of the United States
Preventive Services Task Force, Expanding Newborn Screening: Process, Policy, and Priorities, HASTINGS CENTER
REPORT 38, no. 3, 32-39 (2008).
51 See id.
52
See Recommended Uniform Screening Panel Core Conditions,
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendedpanel/uniformscreeningpa
nel.pdf (as of April 2013). Metabolic Disorders occur when abnormal chemical reactions in your body disrupt the
process your body to make energy from the food you consume. They include Organic Acid Conditions, Fatty Acid
Oxidtion Disorders and Amino Acid Disorders.
53

See id. Endocrine disorders occur when your hormone levels are too high or too low. Hormone diseases also
occur if your body does not respond to hormones the way it is supposed to.
54

See id. Hemoglobin disorders is produced by genes that control the expression of the hemoglobin protein. Defects
in these genes can produce abnormal hemoglobins and anemia
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immunodeficiencies 55 . Currently, no state’s newborn screening panel requires all thirty-one
primary disorders to be screened. However, several states screen for all but one or two disorders.
According to the Genetic Alliance, insurance companies have one year from when a condition is
recommended by the Department of Health and Human Services to provide coverage for the
newly tested conditions.

56

This signifies a remarkable victory for parents, because the new

diseases added by the federal panel will be paid for through insurance because of the
implementation of the ACA.
The Advisory Committee on Heritable Disorders in Newborns and Children also has the
authority to review diseases, disorders and conditions that individuals seek to include on the
Recommended Newborn Screening Panel (RNSP). 57

The RNSP is a comprehensive list

approved and recommended by the Secretary of DHS for states to screen as part of their
individual state newborn screening programs.58 In order to include a condition on the RNSP,
individuals and organizations must partake in an application process wherein they nominate the
condition they desire to by included on the panel.59 The application includes multiple letters in
support of the condition being added, supporting data and scientific/clinical references to support
its inclusion. 60 In addition, conflict of interest disclosures on behalf of the individuals and
organizations must also be submitted.61 Once the application is complete, it is then reviewed by
the Advisory Committee’s Nomination and Prioritization Workgroup who compiles a summary

55

See id.
See Genetic Alliance Applauds Supreme Court Decision on Affordable Care Act,
http://www.geneticalliance.org/genetic-alliance-applauds-supreme-court-decision-affordable-care-act, (Last visited
Dec. 8, 2013).
57
See Discretionary Advisory Committee on Heritable Disorders in Newborns and Children, Nominate a Condition,
http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/nominatecondition/index.html, (last
visited Dec. 8, 2013)
58
See id.
59
See id.
60 See id.
61
See id.
56
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of the information submitted that is then provided to the Secretary of DHS who makes the final
decision as to the disease’s inclusion on the RNSP.62

VI.

NEWBORN SCREENING IN NEW JERSEY AND NEW JERSEY

As stated above, currently, the federal government recommends diseases, disorders and
conditions to be screened through state Newborn Screening programs. As such, each state
adopts its own newborn screening laws, develops its policies and procedures related to the
newborn screening and operates their own individual newborn screening. Thus, the diseases,
disorders and conditions screened for vary from state to state.
In New Jersey and New York, over forty diseases, conditions and disorders are screened
for under their newborn screening laws.63 This section will compare the diseases screened for by
the newborn screening panels in New Jersey and New York.

A. Newborn Screening in New Jersey

Currently, New Jersey has expanded its statewide system of screening to include a total
of fifty-four (54) disorders, diseases and conditions, both primary and secondary as defined by
the RNSP, which, if not detected early, can lead to severe health problems and interfere with the

62

See id.
See What is Newborn Screening, http://www.state.nj.us/health/fhs/nbs/faq.shtml (Last visited Dec. 8 2013);
Wadsworth Center, New York State Department of Health http://www.wadsworth.org/newborn/ (Last visited Dec.
8, 2013).
63
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physical and mental development of the newborn. 64 Together, these fifty-four diseases and
disorders can be characterized into eleven disease groups for further clarification.
The first group of disorders tested under the New Jersey law are Biotinidase Deficiency
disorders. Biotinidase deficiency results from defective activity of an enzyme that links biotin to
other essential substances in the body. 65 A failure to diagnose and treat the deficiency causes
permanent neurological damage and mental retardation in an infant. However, early diagnosis
and treatment with pharmacological doses of biotin produce “marked improvement.” 66 In fact,
pre-symptomatic treatment can result in the normal development of the infant. 67 It will also
enable the infant to lead a healthy life. Testing for these deficiencies are also recommended by
the Secretary of DHS.68
The second group of diseases are characterized as Congenital Adrenal Hyperplasia
(CAH). CAH is a family of disorders whose common feature is an enzymatic defect in the
steroidogenic pathway leading to the biosynthesis of cortisol. 69 The 21-hydroxylase enzyme
deficiency accounts for 90-95% of CAH cases, resulting in ambiguous genitalia in females and
salt-wasting crises in either males or females.70 When infants suffer from Congenital Adrenal
Hyperplasia, their bodies cannot retain salt, which is often referred to as salt-wasting. 71
Treatment for this disorder consists of hormone medications, along with monitoring and lifelong

64

See Disorders Screened in New Jersey, http://www.nj.gov/health/fhs/nbs/disorders.shtml, (Last visited Dec. 8,
2013).
65
See Biontindase Deficiency, http://www.state.nj.us/health/fhs/nbs/biotinidase.shtml, (Last visited Dec. 8, 2013).
66
See Sanford J. Fox &Diony Young, International Protection Of Children's Right To Health: The Medical
Screening Of Newborns, B.C. THIRD WORLD L. J.1, 9 (1991) (discussing biotindase deficiency).
67
See id.
68
See id.
69
See Congenital Adrenal Hyperplasia, http://www.state.nj.us/health/fhs/nbs/cah.shtml, (Last visited Dec. 8, 2013).
70
See id.
71
See id.
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treatments. 72 Detecting this disorder through newborn screening allows an infant to have a
normal life without intellectual and physical disabilities.73
Another group of diseases that are tested for include Congenital Hypothyroidism. Infants
that are born with congenital hypothyroidism are unable to produce adequate amounts of the
thyroid hormone called thyroxine.74 This hormone is integral for the normal function and
development of all of the body’s organs and is essential for the normal development of the
brain.75 Without treatment, this disorder leads to cognitive and intellectual developmental
delays.76 It can also be acquired later on life.77 Treatment for Congenital Hypothyroidism
includes thyroid hormone therapy.78 In addition, infants cannot be fed soy, fiber and iron.79
Under the New Jersey law, cystic fibrosis is another disease that is required to be tested.
According to the NJ State Department of Health, it is the most common recessive genetic
disorder in Caucasians in the U.S., Cystic Fibrosis occurs as a result of a defective Cystic
Fibrosis Transmembrane regulator that results in thick mucus membranes, chronic obstructive
lung disease and recurring pulmonary infections that can lead to death. 80 Cystic Fibrosis can be
treated through nutritional care, such as a high calorie diet. 81 There is no known cure for cystic
fibrosis and antibiotics and medical aggressive airway clearance techniques are often part of the
treatment of this disease.82

72

See id.
See id.
74
See Congenital Hypothyroidism, http://www.state.nj.us/health/fhs/nbs/congenital.shtml, (Last visited Dec. 8,
2013).
75
See id.
76
See id.
77
See id.
78
See Liz Smith, Updated AAP Guidelines on Newborn Screening and Therapy for Congenital Hypothyroidism, 1
AM FAM PHYSICIAN, 439, 441 (2007).
79
See id.
80
See Cystic Fibrosis, http://www.state.nj.us/health/fhs/nbs/fibrosis.shtml, (Last visited Dec. 8, 2013).
81
See id..
82
See id.
73
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Fatty acid oxidation disorders are also tested under the Newborn Screen Program in New
Jersey.83 Fatty acid oxidation disorders are inherited metabolic conditions that impair fatty acid
metabolism.

Each fatty acid oxidation disorder is associated with a specific enzyme

shortcoming.84 The most serious problem associated with fatty acids is that without them, the
body can run out of energy and will often cease to function.85 Without treatment, fatty acids that
cannot be broken down will result in damage to an infant’s heart and liver.86 Through proper
diet, exercise and monitoring, fatty acid oxidation disorders can be controlled, although not
cured. 87
Galactosemia disorders are another condition that is screened for under the New Jersey
newborn screening program. It is an autosomal recessive disorder of carbohydrate metabolism.88
This deficiency results in the build up of galactose in the body, which causes physical symptoms
and discomfort following lactose ingestion. If an infant is found to have this condition, they are
immediately placed on a soy diet and cannot be breastfed. 89 If Galasctosemia disorders are
untreated or not discovered, they can result in the death of the infant.90
Genetic disorders characterized as Sickle Cell Diseases are another group of disorders
that are tested through the newborn screening program in New Jersey. This disorder affects
hemoglobin, which is the molecule in red blood cells used to deliver oxygen throughout the

83

See Fatty Acid Oxidation Disorders, http://www.state.nj.us/health/fhs/nbs/fatty.shtml, (Last visited Dec. 8, 2013).

84

See id.
See Fatty Acid Oxidation Disorders,
http://mydoctor.kaiserpermanente.org/ncal/specialty/genetics/resources/conditions/fatty_acid_oxidation_disorders.js
p, (Last visited Dec. 8, 2013).
86
See id.
87
See id.
88
See Galactosemia, http://www.state.nj.us/health/fhs/nbs/galactosemia.shtml, (Last visited Dec. 8, 2013).
89
See id.
90
See id.
85
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body.91 These diseases are tested in newborns; however, the classic signs and symptoms do not
develop until later on in life.92 In addition, bone marrow transplants often are the only cure for
this disease. However, treatment can be administered through prophylactic antibiotics and
appropriate immunizations to prevent infection.93
Another group of disorders screened for in New Jersey are Maple Syrup Urine Diseases.
These are another autosomal recessive disorder. 94

They are associated with progressive

neurological damage that can lead to death.95 Treatment for these diseases must be continued
throughout life and consist of a strict diet of amino acids.96 Through newborn screening, early
detection of this disease is possible.

In fact, normal development and positive neurologic

outcomes have been observed in infants who started treatment prior to developing this disease.97
Organic Acidemia Disorders are another group of conditions tested under New Jersey’s
newborn screening laws. Organic Acidemias disorders are inherited metabolic disorders that
result in the accumulation of organic acids in blood and urine. 98 Treatment options for this
disorder include low protein diets, carnitine and vitamin supplements. 99 Monitoring of the
infants development is an important part of the treatment for those infants with Organic
Acidemia Disorders.100
The most famous disease tested is Phenylketonuria (PKU). PKU was the first disorder to
be tested through the administration of the newborn screening exam.
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condition in which an infant is unable to breakdown the amino acid phenylalanine in the blood,
which results in mental retardation and developmental delays.101 This disorder is often inherited
and occurs when the body cannot use the amino acid phenylalanine properly.102 Treatment for
PKU must begin as early as possible. It consists of selectively restricting dietary phenylalanine
except for the precise amount needed for the infant’s healthy growth and development.103 This is
preformed by providing infants with a special formula and as they grow and develop, placing
them on a diet that is low in phenylalanine but high in other essential nutrients.104 If treatment is
successful, the infant will be able to have normal physical and mental development.105
The last group of disorders are called Urea Cycle Disorders. Urea cycle disorders are
characterized by an accumulation of ammonia and its precursor amino acids that result in the
defect in the urea cycle.106 Clinical symptoms for this disorder usually appear when the infant is
one to three days old.107 When the disorder develops, the newborn undergoes rapid neurological
deterioration. 108

As the ammonia levels in the child’s body increases, the infant develops

anorexia, hypothermia, irritability and seizures.109 Without intervention, infants often become
comatose and die.110 Treatment for this disease includes providing the correct amount of protein
in the infant’s diet so that they can grow and develop.111
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Most recently, New Jersey became one of the few states to include Krabbe
Leukodystrophy to the New Jersey newborn screening panel. 112 Krabbe disease is an autosomal
recessive lysosmal storage disorder that affects the central nervous system. 113 The significance
of testing for Krabbe disease in New Jersey represents a huge step towards newborn screening of
neurological disorders.
In early 2013, New Jersey became only the fifth state to add Krabbe’s Disease to their
state newborn screening panel.114 This represented a huge victory for advocates of this deadly
neurological disorder as well as the infants born with this disorder. Similar to the other diseases
screened for in New Jersey, Krabbe Disease is an autosomal recessive disorder that is associated
with mutations in the galactosylcermidase gene (GALC). 115 When the GALC gene is mutated, it
produces toxic substances in the brain, causing myelin loss, changes in the brain cells, and severe
neurological damage.116
Unlike some of the diseases tested by newborn screening panels, Krabbe Disease has
variable ages of onset and forms of progression. It is characterized into four types- early
infantile, late infantile, juvenile and adult.117 Children with early-infantile Krabbe disease show
symptoms of developmental delays before six months of age.118 It typically leads to death before
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the age of two.119 Late-infantile Krabbe disease is also deadly and has an onset between six and
three months of age.120 Children with juvenile Krabbe disease become symptomatic between
three and eight years of age and may have a longer survival time. 121 Adult-onset Krabbe disease
is even more inconstant. Affected individuals may have a normal life span.122
The addition of Krabbe disease to the newborn screening panel in New Jersey signifies a
change in the philosophy that newborns should only be screened for treatable or preventable
conditions. Presently, there is no known cure for Krabbe’s Disease. For those infants and
individuals who acquire this disease, treatment is limited to supportive care, palliative care and
drug therapy to control irritability.123 Currently, the only temporary curable treatments available
are the transplantation of umbilical cord blood, hematopoietic stem cell transplantation and
allogeneic bone marrow transplantation.124 These treatments have resulted in less severe signs
and symptoms and significant delays in the onset of symptoms.125
In general, newborn screening in New Jersey is paid for through insurance.126
In addition, initial newborn screening collection forms are purchased by hospitals at a cost of
ninety dollars per form.127 This cost is incorporated into labor and delivery charge.128

B. New York’s Newborn Screening Law
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Similar to the diseases screened by the Newborn Screening Panels in New Jersey, New
York also screens for many of the same diseases, conditions and disorders. Such groups of
diseases and disorders include Endocrine Disorders, which include Congenital Adrenal
Hyperplasia and Congenital Hypothyroidism, various Hempglobinopathies such as Sickle Cell
disease, Amino Acid disorders such as PKU, Fatty Acid Oxidation Disorders, Organic Acid
Disorders and Urea Cycle Disorders.129 In addition, like New Jersey, New York screens for
Biotindase Deficiency, Cystic Fibrosis, and Galactosemia.130
Unlike New Jersey, the major difference between the diseases screened by both states
newborn screening panels is that New York requires the mandatory screening of the Human
Immunodeficiency Virus (HIV). Newborn screening tests in New York examine the infant’s
blood for the presence of HIV antibodies.131 If HIV antibodies are detected in the infant, the
mother is also infected with the virus.132 Under the newborn screening laws in New Jersey, HIV
testing is not mandatory. However, since 1995, regulations in New Jersey have required all
pregnant women to be offered HIV counseling and voluntary HIV tests.133
New York was the first state in the country to include Krabbe Disease to its screening
program in August 2006.134 The impetus for the inclusion of this test by the New York newborn
screening panel came from the advocacy group, Hunter’s Hope who is currently trying to lobby
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all states for the inclusion of this disease in their newborn screening programs.135 They argued
that Krabbe disease should be added to New York’s newborn screening panel because of the
possibility of preventing the disease’s development through chord blood transplants.

136

Newborn screening for Krabbe disease could allow doctors to pre-symptomatically identify if an
infant is susceptible to develop the disease, and treat it.137 Soon after New York began testing
for this disease, other states, such as New Jersey followed.

VII.

INCLUSION OF ALZHEIMER’S DISEASE TO NEWBORN SCREENING PANELS

There is a valid argument for including Early-onset Alzheimer’s disease on the list of
diseases tested on newborn screening panels in New Jersey, New York and most importantly on
Federally recommended list. Through scientific advancements and technology, it is easy to
predict if one is a carrier of this degenerative, neurological disorder. In addition, since this type
of Alzheimer’s is the most rare form, individuals susceptible to this disorder should have the
right to know that they may acquire it.
Furthermore, unlike Krabbe’s disease, which is already included in some newborn
screening panels, a neurological disorder for which there is no cure, science has demonstrated
that through intervention and therapy, the risk of developing Early-onset Alzheimer’s disease
may be reduced by living a particular type of lifestyle138. This is something that can be taught to
children who have an increased risk of developing this disease. Therefore, if states such as New
Jersey and New York are at the forefront in beginning to screen newborns for neurological
135
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disorders that are deadly, they should consider screening for neurological disorders whose onsets
can be delayed.

A. Overview of Early- Alzheimer’s Disease

Alzheimer’s disease is a degenerative disease of the brain that results in dementia. 139
According to the National Institute of Dementia and Stroke, dementia occurs when brain cells
die.140 Brain cell death is not an immediate occurrence.141 Rather, it is progressive and occurs
over time.142 Symptoms of dementia include the gradual loss of memory, judgment and the
ability to process information so that an individual may function.143
There are two types of Alzheimer’s disease: early onset or familial and late-onset. Early
on-set Alzheimer’s disease occurs in those individuals who acquire the disease at age sixty-five
(65) or under.144 This article solely focuses on the genetic testing of children for Early-onset
Alzheimer’s disease as it is the type of Alzheimer’s that is the rarest and most easily detected
through genetic testing.
The genetic origin of Early-onset Alzheimer’s disease is easily understood. Most cases
of Early-onset Alzheimer disease are caused by gene mutations that can be passed from parent to
child.145 The Early-onset familial form of the disease can arise in individuals who are in their
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forties and fifties, and in very rare cases can develop in people who are thirty years of age. 146
However, it is generally characterized as occurring in individuals age sixty-five (65) and
under.147 With this familial form of Early-onset Alzheimer's, there usually will be many parents,
siblings and cousins who acquire the disease and also have dementia.148 When an individual is a
carrier of one of the gene mutations that cause Early-onset Alzheimer’s disease to develop, it is a
good predictor that they are susceptible to develop this debilitating disease.149
As the progression of the disease worsens, people with Early-onset Alzheimer’s disease
experience personality and behavioral changes that make social integrations difficult for them.150
As a result, individuals suffering from this disease experience frequent agitation, restlessness,
withdrawal and even the loss of language skills.151
The genes associated with Alzheimer’s disease are amyloid precursor protein (APP),
Presenilin (PSEN-1 and PSEN-2) and appolipoprotient (APOE).152 Mutations in APP result in
an incorrect amount of the protein, which produces a version of amyloid β that is more likely to
form plaques. Mutations in APP account for ten to fifteen percent of familial Early-onset
Alzheimer's disease cases.153 The PSEN genes encode proteins that function in the cleavage of
Amyloid Precursor Protein.154 Mutations in both PSEN1 and PSEN2 result in incorrect cleavage
of APP, and are associated with the development of familial Early-onset Alzheimer’s disease.155
Mutations in PSEN1 are thought to account for 30%-70% of familial Early-onset Alzheimer
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disease developments, while mutations in PSEN2 are thought to account for less than 5%.156
Children of an affected parent have a 50% chance of inheriting the mutation and
developing Early-onset Alzheimer’s Disease. It is important to note that mutations in APP,
PSEN1 and PSEN2 do not account for all of the genes that result in familial early-onset
Alzheimer’s disease.157 In fact, scientists believe that there are other genes that attribute to this
disease that are not known at this time and likely to be discovered in the future. 158 However,
mutations in these genes will likely lead to the development of Early-onset Alzheimer’s disease.

B. Therapy, Prevention and Intervention

In addition to genetics in predicting the possibility of acquiring Early-onset Alzheimer’s
Disease, environmental factors, lifestyle choices, among many other factors can also attribute to
the development of the disease.159 Thus, with this known, it is important to know whether an
infant is a carrier of the genes in order to delay the progression and onset of the Early-onset
Alzheimer’s disease occurring later on in life. Therefore, the testing for the genes associated
with Early-onset Alzheimer’s disease is important to include in newborn screening programs so
that the onset of the disease is delayed and individuals can have a longer and healthier quality of
life.
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Over the last three decades, researchers have found that parents who warn their children
about the risk of developing Alzheimer’s Disease has lead to its delayed development. 160
Knowledge is power. Knowing this from a very young age, leads to, what scientists refers to as
“building your cognitive reserve.” According to this theory, by exercising and developing the
mind as early as possible, later on in life, when Early-onset Alzheimer’s Disease begins to
deteriorate the brain, people with the largest and most comprehensive cognitive reserves would
experience less brain deterioration. 161

Cognitive reserve has also been used to explain the

neuropatholgic changes associated with coping with Alzheimer’s disease.162 According to the
American Academy of Neurology, cognitive reserve capacity is set early on in life and gradually
changes as the nervous system changes. 163 As individuals age, those with a higher reserve
capacity will have a lower risk of developing dementia. 164 This is significant, because, since
Early-onset Alzheimer’s disease is very predicable through genetic testing, families should have
the right to know that their children are carriers of genes so that they can start cognitive therapy
early on in life.
Another treatment recommended for the prevention of Alzheimer’s is physical,
cardiovascular exercise. 165

The scientific and medical communities have established that

evidence suggests that cholesterol plays a role in the development of Alzheimer disease in
general.166 Therefore, individuals who build in regular cardiovascular exercise into their daily
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routine are less likely to develop Early-onset Alzheimer’s disease.167 In fact, individuals who
exercised regularly have about half the risk of developing dementia then those who do not
exercise. Therefore, it is important for children to be brought up knowing the importance of
exercising and engaging in actual exercise so that those, who are carriers of the genes associated
with Early-onset Alzheimer’s disease, can reduce their risk of acquiring the disease later on in
life.168
Finally, a change in diet may reduce the risk of developing Early-onset Alzheimer’s
Disease.169 According to the Physician’s Committee for Responsible Medicine, there are seven
dietary principles that are proven to reduce the risk of Alzheimer’s disease.170 These principles
were revealed during the International Conference on Nutrition and the Brain.171 They include
reducing your intake of saturated and trans fats and cooperating vegetables, fruits and whole
grains into your diet. 172 Those individuals who are susceptible to developing Early-onset
Alzheimer’s disease should incorporate Vitamin E and B12 into their daily vitamins.

When

selecting multiple vitamins, those at risk for Early-onset Alzheimer’s disease should avoid iron
and copper.173 Providing this information to parents enables them to educate their children and,
through physician supervision, integrate these vitamins into their children’s daily diet.

C. Ethical Considerations and Policy Recommendations
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While the technology is available for Early-onset Alzheimer’s disease to be screened in
newborns, there are still several ethical questions that arise, especially since even the earliest
indications of this disease occur once a child has matured into an adult. In particular, it is
important for parents to proceed with caution in acquiring this information and utilizing it in
their child’s daily life.
The genetic testing for Early-onset Alzheimer’s disease in newborns can present some
ethical problems in regard to the child’s autonomy. This discussion ultimately focuses on whose
right to autonomy is jeopardized; the parents or the childs, when there is no immediate identified
medical benefit. If parents chose to have their child tested to their susceptibility for obtaining
Early-onset Alzheimer’s disease, the child’s right to autonomy is violated. However, with the
technology available to predict this disease in infants, there is an argument to be made that
denying this test to parents deprives their children of health care that could provide them with a
better quality of life.
In addition, the physiological effects of telling a child that they are susceptible to
developing Early-onset Alzheimer’s disease still needs to be determined.

Children are

vulnerable and basically telling a child that they will one day lose their ability to remember
memories and information can have detrimental effects on the child’s development. The
scientific and medical communities are yet to determine the implications that result from when a
child learns this information. In addition, their still needs to be more information available as to
what the appropriate age is a that a child should learn that they are likely to develop Early-onset
Alzheimer’s disease in the future.
Furthermore, if infants and children are treated for their susceptibility in developing
Early-onset Alzheimer’s disease, there needs to be strict physician guidance in overseeing these
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treatments. Also, guidelines need to be implemented as to what types of treatments can be used
in children and the safety of these treatments. This guidance should be established on the federal
level so that a least, minimum standards are developed through state implementation.
Infants with negative or unclear newborn screening test results also need have the
newborn screening test re-administered to them. This re-administration should be performed at
no additional cost to parents. Rather, should either be paid for through insurance or by the state.
As to the unification of newborn screening panels nationwide, there needs to be an
incentive for states to adopt all the diseases recommended by the Uniform Screening Panel. By
doing so, this will ensure that all newborns are screened for diseases that can save their lives.
This should not be viewed as a mandate or a political agenda. Rather, it should be considered a
public health initiative.

The Secretary of DHS should evaluate the current list of diseases

screened, together with all the other diseases that states screen for to make “master” list of
diseases that should be screened. This process would appear to be faster then the current process
of medical professionals and individuals submitting an application to the Department for review.
Together, it is important that these ethical considerations and policy recommendations are
considered when adding Early-onset Alzheimer’s disease to newborn screening panels.

D. Application of the Wilson and Jungner Test Supports Adding Early-onset
Alzheimer’s Disease to Newborn Screening Panels
In addition to these treatments proven to delay the onset of Early-onset Alzheimer’s
disease, it also passes the Wilson and Jungner classic screening criteria for inclusion on newborn
screening panels discussed is Part I, Section A.
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According to Wilson and Jungner, there are five criteria that must be met for a genetic
disorder to be screened.174 According to them, in order for a disease to be screened, it must be
well defined and serious.175 Early-onset Alzheimer’s disease is a defined neurological disorder
that results in clinical symptoms resulting in the progression of cognitive and behavioral
impairment. 176 Therefore, the disease is defined as serious as required under the Wilson and
Jungner criteria.
Second, Wilson and Jungner state that there must be an accurate testing method available
for the genetic disease.177 The Newborn Screening Quality Assurance Program (NSQAP) is a
voluntary, non-regulatory program established by the federal government to aid state health
departments and their laboratories in maintaining accurate newborn screening test results.178 The
NSQAP provides proficiency-testing services, which give state laboratories, coded specimens of
the diseases screened to help scientists and doctors determine the results of the administered
newborn screening test. 179

Therefore, there is accurate testing available for Early-onset

Alzheimer’s disease.
Third, the costs of the test must be reasonable. According to the New Jersey State
Department of Health, the cost of newborn screening is covered through insurance so it is
reasonable.180 In New York, the cost of newborn screening is absorbed by the state. Therefore,
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the cost of newborn screening to detect Early-onset Alzheimer’s disease is reasonable as there
are already numerous diseases that states and insurance companies pay for that are tested.
The forth criteria established by Wilson and Jungner is that there must be available
treatment for the disorder. 181

Recent medical studies have indicated that there is treatment

available to help delay the onset of Alzheimer’s disease in general. 182 Such therapies and
treatments include exercising and developing the mind as early as possible. Therefore, it this
criterion is also satisfied.
The last Wilson and Jungner criterion is that there must be adequate medical management
facilities to refer infants for confirmatory diagnosis and treatment.183 This is satisfied though the
sophistication of hospitals and medical facilities. In addition, health care systems across the
county are developing specific treatment centers for Alzheimer’s diseases treatment. Most
recently, Capitol Health’s Institute for Neuroscience announced that it will be opening a
specialized program focusing on the treatment of Alzheimer’s disease in New Jersey.184
Based upon the above analysis, it is evident that Early-onset Alzheimer’s disease passes
renowned criteria set forth by Wilson and Jungner needed for diseases to be included in newborn
screening panels. If we were to apply this same test to Krabbe’s disease, in which there is no
cost-effective treatment for and no known cure, it appears that it would not pass the Wilson and
Judger test. Despite this, New Jersey and New York have already added this disorder to their
state newborn screening panel. Therefore, this provides a strong argument for the inclusion of
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Early-onset Alzheimer’s disease to newborn screening panels at least on the federal Uniform
Newborn Screening Panel.

V. CONCLUSION

This paper discussed the importance of states adopting all of the diseases recommended
by the RNSP to their individual newborn screening programs. If this is not accomplishment,
there is a possibly that some infants will die as a result of their state not choosing to screen for a
particular disease recommended by the RNSP. Evidence of this has already occurred from some
states not choosing to screen for Krabbe disease as discussed above. It the testing and treatment
is available to save the lives of infants, not utilizing it is a foolish.
In addition, this paper also discussed the importance of including Early-onset
Alzheimer’s disease to the list of federally recommended screened diseases, conditions and
disorders approved by the Secretary of DHS. Based upon the information known about Earlyonset Alzheimer’s disease and the medical research available that confirms possible treatments
and interventions for the disease, it is clear that this disease should be added to the federal list of
diseases that are recommended to be screened for in newborns. In addition, addition Early-onset
Alzheimer’s disease passes the criteria for screening diseases established by Wilson and Jungner.
As evidenced in this paper, Krabbe disease, which is already screened for by some states does
not pass this well-established criteria. It is important to note that there are treatments and
interventions available to delay the onset of Early-onset Alzheimer’s disease. Therefore, this
presents a strong argument that favors adding Early-onset Alzheimer’s disease to the federal
panel.
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Furthermore, with the ACA requirement that all diseases recommended by the federal
panel be paid for through insurance, more infant lives will be saved, regardless of whether or not
their state screens for the disease. This is a significant advancement in newborn screening and
demonstrates the importance of screening infants for all the diseases federally recommended.
Therefore, Early-onset Alzheimer’s disease should be added to the Recommended Newborn
Screening Panel. If this cannot be accomplished, Early-onset Alzheimer’s should be included as
a disease tested in New York and New Jersey’s newborn screening panels.
With the ability to test if an infant is a carrier of the genes associated with Early-onset
Alzheimer’s disease, medical research suggests that through therapies and interventions, its onset
can be delayed. Therefore, the testing for these genes is important so that those individuals who
are susceptible for acquiring Early-onset Alzheimer’s disease can have a healthier and better
quality of life and slow the progression of this devastating illness.
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